Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

Abstract

Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High‐grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high‐grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2–11 and intron–exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic TP53 mutations were identified in 96.7% ( n = 119/123) of HGPSC cases. Molecular and pathological review of mutation‐negative cases showed evidence of p53 dysfunction associated with copy number gain of MDM2 or MDM4 , or indicated the exclusion of samples as being low‐grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between TP53 mutation and progression‐free or overall survival was found. From this first comprehensive mapping of TP53 mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers. Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 50

1. 1.

   Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Rev Cancer. 2009;9:701-713.

   Not in our library10.1038/nrc2693

2. 2.

   Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991;51:2979-2984.

   Not in our library

3. 3.

   Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res. 1991;51:5171-5176.

   Not in our library

4. 4.

   de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer. 2009;101:149-159.

   Not in our library10.1038/sj.bjc.6605112

5. 5.

   Hall J, Paul J, Brown R. Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med. 2004;6:1-20.

   Not in our library10.1017/s1462399404007781

6. 6.

   Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nature Rev Cancer. 2006;6:83-90.

   Not in our library10.1038/nrc1783

7. 7.

   Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal Fallopian tube. J Pathol. 2007;211:26-35.

   Not in our library10.1002/path.2091

8. 8.

   Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal Fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3-9.

   Not in our library10.1097/gco.0b013e328011a21f

9. 9.

   Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM, et al. Serous ovarian, Fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer. 2008;122:1598-1603.

   Not in our library10.1002/ijc.23287

10. 10.

    Herrington CS, McCluggage WG. The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol. 2007;220:5-6.

    Not in our library10.1002/path.2630

11. 11.

    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184.

    Not in our library10.1093/jnci/dji237

12. 12.

    Olivier M, Petitjean A, Marcel V, Petre A, Mounawar M, Plymoth A, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009;16:1-12.

    Not in our library10.1038/cgt.2008.69

13. 13.

    Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203-206.

    Not in our library10.1038/378203a0

14. 14.

    Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet. 2001;29:92-95.

    Not in our library10.1038/ng714

15. 15.

    Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80-83.

    Not in our library10.1038/358080a0

16. 16.

    McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer. 1995;71:981-985.

    Not in our library10.1038/bjc.1995.189

17. 17.

    Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000;89:2006-2017.

    Not in our library10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.3.co;2-z

18. 18.

    Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res. 2006;12:1157-1167.

    Not in our library10.1158/1078-0432.ccr-05-1029

19. 19.

    Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, et al. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle. 2009;8:3396-3405.

    Not in our library10.4161/cc.8.20.9910

20. 20.

    Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267-282.

    Not in our library10.1097/pap.0b013e3181b4fffa

21. 21.

    Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res. 2005;11:7273-7279.

    Not in our library10.1158/1078-0432.ccr-05-0755

22. 22.

    Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24:1053-1065.

    Not in our library10.1038/sj.onc.1208298

23. 23.

    Salani R, Kurman RJ, Giuntoli R, Gardner G, Bristow R, Wang TL, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer. 2008;18:487-491.

    Not in our library10.1111/j.1525-1438.2007.01039.x

24. 24.

    Dehari R, Kurman RJ, Logani S, Shih IeM. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol. 2007;31:1007-1012.

    Not in our library10.1097/pas.0b013e31802cbbe9

25. 25.

    Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003;112:779-791.

    Not in our library10.1016/s0092-8674(03)00193-4

26. 26.

    Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 2004;429:86-92.

    Not in our library10.1038/nature02514

27. 27.

    Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, Thomssen C, et al. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res. 2008;14:89-96.

    Not in our library10.1158/1078-0432.ccr-07-1192

28. 28.

    Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers. A Gynecologic Oncology Group study. Gynecol Oncol. 2008;111:487-495.

    Not in our library10.1016/j.ygyno.2008.08.020

29. 29.

    Hogdall EV, Christensen L, Hogdall CK, Frederiksen K, Gayther S, Blaakaer J, et al. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS. 2008;116:400-409.

    Not in our library10.1111/j.1600-0463.2008.00917.x

30. 30.

    Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, et al. TP53 status and taxane–platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer. 2008;8:27.

    Not in our library10.1186/1471-2407-8-27

31. 31.

    Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.

    Not in our library10.1038/356215a0

32. 32.

    Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008;22:1337-1344.

    Not in our library10.1101/gad.1662908

33. 33.

    Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res. 2008;68:1723-1731.

    Not in our library10.1158/0008-5472.can-07-1963

34. 34.

    Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst. 1999;91:469-473.

    Not in our library10.1093/jnci/91.5.469

35. 35.

    Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 2009;69:3625-3633.

    Not in our library10.1158/0008-5472.can-08-3426

36. 36.

    Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nature Rev Cancer. 2004;4:814-819.

    Not in our library10.1038/nrc1457

37. 37.

    Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-6430.

    Not in our library10.1158/1078-0432.ccr-05-0508

38. 38.
    Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies · 2008

    No notice
39. 39.

    Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505-515.

    Not in our library10.1016/s0140-6736(02)09738-6

40. 40.

    Etemadmoghadam D, de Fazio A, Beroukhim R, Mermel C, George J, Getz G, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009;15:1417-1427.

    Not in our library10.1158/1078-0432.ccr-08-1564

Cited by papers we hold 23

• Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones · 2024
  No notice
• Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer · 2022
  No notice
• Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) · 2021
  No notice
• Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes · 2021
  No notice
• The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents · 2020
  No notice
• Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium · 2019
  Not checked
• A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids · 2019
  No notice
• Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma · 2018
  No notice
• The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway · 2018
  Not checked
• The extracellular matrix of ovarian cortical inclusion cysts modulates invasion of fallopian tube epithelial cells · 2018
  Not checked
• Cell Origins of High-Grade Serous Ovarian Cancer · 2018
  No notice
• Insights into the Dichotomous Regulation of SOD2 in Cancer · 2017
  No notice
• A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models. · 2016
  Not checked
• Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing · 2016
  No notice
• Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study · 2016
  No notice
• Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis · 2015
  No notice
• APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells · 2015
  No notice
• Methylation of cell-free circulating DNA in the diagnosis of cancer · 2015
  No notice
• TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data · 2014
  No notice
• Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes · 2014
  Corrected

and 3 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.